Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

Covenant Health, US

Status: Enrolling

Conditions: Alzheimer Dementia; Encephalopathy; Delirium Confusional State; Alzheimer Disease; Cognitive Abnormality

Treatments: Diagnostic Test: Quest AD-Detect blood test

Study type: Interventional

Funder types: Other

Identifiers

NCT07222280

ADUE2025

Details and patient eligibility

About

The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease.

• Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting?
• Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio

Enrollment: 30 estimated patients

Sex: All

Ages: 60 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ages 60 to 90 years old
• No prior diagnosis of dementia
• Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state

Exclusion criteria

• Age under 60 years
• Prior diagnosis of dementing illness or other organic etiology to cognitive impairment

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

All eligible patients will receive a Quest AD-Detect blood test

Other group

Description:

All patients that meet the inclusion criteria, and none of the exclusion criteria, will have their blood tested with the Quest AD-Detect

Treatment:

Diagnostic Test: Quest AD-Detect blood test